Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 2/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16907675 | 0.92 | GAA (0.37) | GAAPOLBSMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL18607971 | 0.91 | POLB (0.36) | GAAPOLBSMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL23652596 | 0.88 | GAA (0.33) | GAAPOLBSMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL16222416 | 0.87 | GAA (0.38) | GAAPOLBSMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL16222213 | 0.87 | GAA (0.38) | GAAPOLBSMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL17589373 | 0.86 | GAA (0.35) | GAAPOLBSMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL16904629 | 0.86 | GAA (0.32) | GAA | |
| SCHEMBL15182437 | 0.86 | GAA (0.32) | GAAPOLBALDH1A1 | |
| SCHEMBL16177753 | 0.85 | GAA (0.35) | GAAPOLBSMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL22172270 | 0.85 | GAA (0.33) | GAAPOLBSMN1; SMN2LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4400168-A2 | ANTISENSE NUCLEIC ACIDS | Nippon Shinyaku Co., Ltd. (JP) | 2024-07-17 | — | — | EP | disclosed |
| EP-4389893-A1 | HUMAN TRANSFERRIN RECEPTOR BINDING PEPTIDE-DRUG CONJUGATE | Takeda Pharmaceutical Company Limited (JP) | 2024-06-26 | — | — | EP | disclosed |
| WO-2024112809-A2 | CELL-PENETRATING PEPTIDES, CONJUGATES THEREOF, AND METHODS OF THEIR USE | PEPGEN INC. (US) | 2024-05-30 | — | — | WO | disclosed |
| US-11911403-B2 | Antisense-induced exon exclusion in type VII collagen | SAREPTA THERAPEUTICS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11802283-B2 | Oligonucleotide analogues targeting human LMNA | SAREPTA THERAPEUTICS, INC. (US) | 2023-10-31 | — | — | US | disclosed |
| US-11802283-B2 | Oligonucleotide analogues targeting human LMNA | SAREPTA THERAPEUTICS, INC. (US) | 2023-10-31 | — | — | US | disclosed |
| WO-2023282346-A1 | PRECIPITATION INHIBITOR | 日本新薬株式会社 | 2023-01-12 | — | — | WO | disclosed |
| WO-2023282344-A1 | NEPHROTOXICITY REDUCING AGENT | 日本新薬株式会社 | 2023-01-12 | — | — | WO | disclosed |
| WO-2023282345-A1 | NEPHROTOXICITY REDUCING AGENT | 日本新薬株式会社 | 2023-01-12 | — | — | WO | disclosed |
| EP-4112083-A1 | ANTISENSE NUCLEIC ACID INDUCING SKIPPING OF EXON 51 | Nippon Shinyaku Co., Ltd. (JP) | 2023-01-04 | — | — | EP | disclosed |
| WO-2016149659-A2 | ANTISENSE-INDUCED EXON EXCLUSION IN MYOSTATIN | Serepta Therapeutics, Inc. (US) | 2016-09-22 | — | — | WO | disclosed |
| US-20160208264-A1 | ANTISENSE-INDUCED EXON2 INCLUSION IN ACID ALPHA-GLUCOSIDASE | SAREPTA THERAPEUTICS, INC. | 2016-07-21 | — | — | US | disclosed |
| EP-2612917-B1 | ANTISENSE NUCLEIC ACID | NIPPON SHINYAKU CO LTD (JP) | 2016-02-24 | — | — | EP | disclosed |
| US-20150197534-A1 | ANTISENSE-INDUCED EXON2 INCLUSION IN ACID ALPHA-GLUCOSIDASE | SAREPTA THERAPEUTICS, INC. | 2015-07-16 | — | — | US | disclosed |
| US-9079934-B2 | Antisense nucleic acids | NIPPON SHINYAKU CO., LTD. (JP) | 2015-07-14 | — | — | US | disclosed |
| US-20150166995-A1 | ANTISENSE NUCLEIC ACIDS | NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY (JP) | 2015-06-18 | — | — | US | disclosed |
| US-20140343266-A1 | ANTISENSE NUCLEIC ACIDS | NIPPON SHINYAKU CO., LTD. (JP) | 2014-11-20 | — | — | US | disclosed |
| US-20130211062-A1 | ANTISENSE NUCLEIC ACIDS | NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY (JP) | 2013-08-15 | — | — | US | disclosed |
| EP-2612917-A1 | ANTISENSE NUCLEIC ACID | Nippon Shinyaku Co., Ltd. (JP) | 2013-07-10 | — | — | EP | disclosed |
| WO-2013100190-A1 | ANTISENSE NUCLEIC ACID | 日本新薬株式会社 (JP) | 2013-07-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150197534-A1 | ANTISENSE-INDUCED EXON2 INCLUSION IN ACID ALPHA-GLUCOSIDASE | GAA, GBA3, GBA2 | GAA 1/4885POLB 395/4885SMN1; SMN2 62/4885 |
| US-11802283-B2 | Oligonucleotide analogues targeting human LMNA | LMNB2, LMNA, LMNB1 | GAA 848/4885POLB 145/4885SMN1; SMN2 23/4885 |
| US-11911403-B2 | Antisense-induced exon exclusion in type VII collagen | COL2A1, COL14A1, COL1A1 | GAA 1191/4885POLB 42/4885SMN1; SMN2 416/4885 |
| US-20130211062-A1 | ANTISENSE NUCLEIC ACIDS | UTRN, RBM17, UPF1 | GAA 1160/4885POLB 221/4885SMN1; SMN2 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.